Does plasma phoenixin level associate with cognition? Comparison between subjective memory complaint, mild cognitive impairment, and mild Alzheimer's disease

Yuruyen M., Gultekin G., Batun G. C., Yavuzer H., Akcan F. E., Doventas A., ...More

INTERNATIONAL PSYCHOGERIATRICS, vol.29, no.9, pp.1543-1550, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 9
  • Publication Date: 2017
  • Doi Number: 10.1017/s1041610217000825
  • Journal Name: INTERNATIONAL PSYCHOGERIATRICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus
  • Page Numbers: pp.1543-1550
  • Istanbul University Affiliated: Yes

Abstract

Background: Alteration in energy expenditure or metabolism is the most accused risk issue for the onset and for the course of neurodegenerative cognitive disorders. Neuropeptides are suggested to be related with learning and memory. Phoenixin (PNX) is the most recently reported neuropeptide and we aimed to compare the plasma level in people with subjective memory complaints, patients with mild cognitive impairment, and mild Alzheimer's disease (AD).